StockNews.AI
LSTA
StockNews.AI
180 days

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

1. LSTA will report 2024 financial results on Feb 27, 2025. Conference call follows market closing. 2. Lisata is advancing innovative therapies for advanced solid tumors. Its cyclic peptide, certepetide, aims to improve tumor targeting. 3. Key R&D and commercial partnerships bolster the CendR Platform®. Milestones over the next 1.5 years are anticipated.

Earnings
+0.8%Current Return
VS
-2.08%S&P 500
$2.502/20 08:08 AM EDTEvent Start
$2.5202/21 02:31 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report is a standard catalyst in a clinical-stage company. Past earnings announcements for similar biotech firms have often shown muted immediate effects until data surprises emerge.

How important is it?

The announcement sets the stage for critical financial disclosure and future milestones. While it is a standard earnings event, potential data updates and forward-looking milestones add moderate importance.

Why Short Term?

Earnings results and related conference calls typically drive short-term price action. Although future milestones hint at longer-term potential, the immediate impact is expected to be limited.

Related Companies

NVAXBIIB
February 20, 2025 08:00 ET  | Source: Lisata Therapeutics, Inc. BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the twelve months ended December 31, 2024, on Thursday, February 27, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months. About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com. Contact: Investors:Lisata TherapeuticsJohn MendittoVice President, Investor Relations and Corporate CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com Media:ICR HealthcareElizabeth ColemanAccount SupervisorPhone: 203-682-4783Email: elizabeth.coleman@icrhealthcare.com This press release was published by a CLEAR® Verified individual.

Related News